Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

MNA-001

Source date not recordedAnalyse record ↗

Investigational TREM2 agonist intended to enhance protective microglial responses and clearance of misfolded proteins and cellular debris in early Alzheimer's disease.

Modality
oral brain-penetrant small-molecule TREM2 agonist
Availability (US)
Phase 1; ongoing in the cited January 2026 company update
Biomarkers
TREM2 target engagement and activation in plasma and CSF; pharmacokinetics; microglial function
Hallmark targeted
loss of proteostasis, disabled autophagy, chronic inflammation, altered intercellular communication
Kind
investigational drug
Clinical trials
Phase 1 randomized SAD/MAD study in healthy adult and elderly participants